Four blue-chip stocks in India have demonstrated consistent margin expansion over the past three years, according to reports from Equitymaster.com. These established companies have strengthened their profitability across diverse sectors including steel, engineering, aerospace, and pharmaceuticals. The margin improvements indicate these companies have successfully optimized their operations and business models during this period.
Tata Steel Ltd, one of the world's leading steel producers, has shown remarkable margin improvement across its diversified portfolio. As reported by Equitymaster.com, the company's operating profit margin increased from 10.5% in FY24 to 12.3% in FY25 and 15.4% in FY26. More significantly, the company's net profit margin turned positive, improving from -2.1% in FY24 to 1.5% in FY25 and 4.7% in FY26. The company serves customers across automotive, industrial, branded products, and services segments through its steel value chain presence.
Cummins India Ltd, a leading manufacturer of diesel and natural gas engines, has maintained strong profitability across its three key business segments. According to Equitymaster.com, the company's operating profit margin increased from 23.9% in FY24 to 24.3% in FY25 and 25.6% in FY26. Net profit margin also improved from 19.1% to 19.2% and 19.4% over the same period. The company manufactures engines ranging from 125 HP to 4,000 HP for commercial vehicles and off-highway applications including construction and mining sectors.
Hindustan Aeronautics Ltd (HAL) has demonstrated strong margin expansion in its aerospace manufacturing operations. As reported by Equitymaster.com, the company's operating profit margin rose from 38.3% in FY24 to 39.3% in FY25 and 40.8% in FY26. Net profit margin also increased from 25.1% to 27% and 27.5% over the same period. HAL primarily serves India's defence forces including the Indian Air Force, Army, Navy, and Coast Guard, manufacturing aircraft like Su-30 MKI, LCA, and helicopters including ALH-Dhruv and Chetak models.
Lupin Ltd, a leading pharmaceutical company operating across 100+ countries, has shown the most dramatic margin improvement among the four companies. According to Equitymaster.com, the company's operating profit margin surged from 19.6% in FY24 to 24.1% in FY25 and 33.1% in FY26. Net profit margin also increased significantly from 9.7% to 14.6% and 19.2% over the same period. The company operates across generics, biotechnology, and active pharmaceutical ingredients with strong presence in cardiovascular, diabetes, respiratory, and anti-infective medicines.
